InsiderTrades

Form 4 for EBS Emergent BioSolutions Inc.

Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-06 · accession 0001961994-26-000003 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
2026-02-10 2026-02-06 EBS Williams Paul Anthony SVP, Products Business D - Sale to Iss $10.92 -8,655 77.2K -10% -$94.5K
2026-02-10 2026-02-06 EBS Williams Paul Anthony SVP, Products Business F - Tax $10.92 -1,022 76.2K -1% -$11.2K

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-06 D D 8,655 $10.92 77,216 D — — (F1) Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 2,884 shares of common stock, which is less than the 11,539 shares previously reported on March 02, 2023 and June 09, 2023.
2 Common Common Stock 2026-02-06 F D 1,022 $10.92 76,194 D — — (F2) Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units